Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Company Overview - Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions [5]. Product Development - Tecarfarin is being developed for unmet needs in anticoagulation therapy and has received orphan drug designation from the FDA for preventing thrombosis and thromboembolism in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVAD) [3]. - The drug also has orphan drug and fast-track designations from the FDA for preventing systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib) [3]. - Tecarfarin has been evaluated in eleven human clinical trials involving more than 1,000 individuals, demonstrating general tolerability in both healthy adults and patients with chronic kidney disease [3]. Upcoming Events - Cadrenal will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 4:15 pm ET, with a webcast link available on the investor relations page of the company's website [1]. - Management will also host one-on-one investor meetings after the conference, with interested parties encouraged to contact the company's investor relations team [2].